Seeking to carve out its own niche in the obesity space, Syntis Bio launched today to develop an oral weight-loss treatment that mimics the effects of gastric bypass surgery.
Tag Archive for: GLP-1 drugs
Monthly medication subscription to the retailer’s virtual healthcare platform, Whole Health Rx, starts at an introductory price of $219, and does not require insurance, the company said in a statement.
IRIS offers immersive insights reports and live dashboards designed to help the healthcare industry and other stakeholders anticipate and identify transformative market events, and how best to strategically navigate the fast-moving environment.
Sen. Bernie Sanders (I-Vt.) on Wednesday launched an investigation into the exorbitant prices of Novo Nordisk’s Ozempic and Wegovy blockbusters, and has asked the Danish drugmaker to justify their price tags.
The trial results add to a growing body of clinical evidence that suggests GLP-1 drugs, which include popular treatments such as Lilly’s Mounjaro and Novo Nordisk’s Wegovy, have medical benefits beyond diabetes and weight loss.
The cybersecurity firm BrandShield has taken down more than 250 websites selling fake versions of popular weight-loss and diabetes drugs in the GLP-1 class, the company’s CEO Yoav Keren told Reuters.
German packaging and medical equipment maker Gerresheimer has contracts with the leading players in the burgeoning weight-loss drugs sector, CEO Dietmar Siemssen said after the company reported first-quarter earnings on Thursday.
Multiple doses of Eli Lilly’s top-selling diabetes medication Mounjaro (tirzepatide) will be in short supply through April 2024, according to the FDA’s database for drug shortages and discontinuations.
Now in Phase III with its small molecule orforglipron, Eli Lilly is leading the oral GLP-1 race against Novo Nordisk, Pfizer, Roche and others.
Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone. Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity. These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.